COULD VALO HEALTH BECOME ONE OF FLAGSHIP PIONEERING’S BIGGEST COMPANIES YET?

The investment firm Flagship Pioneering has incubated a lot of life sciences companies since it was founded in 2000. In fact, while a general partner with Flagship Pioneering over the last 15 years, David Berry has started more than 30 companies, five of which trade publicly right now: Seres Therapeutics, Sensen Bio, Evelo Biosciences, T2 Biosystems and Axcella Health.

Berry is often a company’s first CEO, then transitions out of the company within 18 months. But he has no plans to leave his post as CEO of Valo Health, a three-year-old, Boston-based, 110-person drug discovery company that Berry and Flagship seem to think could become one of the firm’s most important companies yet. That’s notable, considering that Flagship incubated 11-year-old Moderna, which currently boasts a $50 billion market cap thanks in large part to its coronavirus vaccine.

Perhaps it’s no surprise, given Berry’s and Flagship’s track record, that Valo has attracted believers. Notably, today it is announcing a fresh $110 million in extended Series B financing from Koch Disruptive Technologies that brings the round total to $300 million and the overall amount the young company has raised to more than $450 million.

Continue reading…

Share on facebook
Share
Share on twitter
Tweet
Share on linkedin
Share

More To Explore